title: Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
abstract: Amifostine (WR-2721; Ethyol) is a well-known cytoprotector, but a possible role in preventing extrahaematological toxicity after high-dose therapy (HDT) has never been investigated. We compared two historical groups of patients who either received (group A, n = 35) or did not receive (group B, n = 33) amifostine (740 mg/m2) before high-dose (HD) melphalan, followed by autologous infusion of peripheral blood progenitor cells (PBPCs). Amifostine was well tolerated at this dose level. Emesis grade 1-2 was the most important side-effect, but the interruption of infusion was never required. The incidence and median duration of severe mucositis (grade 3-4) was 21% and 0 d (range 0-11 d) in group A and 53% and 7 d (range 0-11 d) in group B. The duration of analgesic therapy was also significantly lower in group A (0 d; range 0-12) than in group B (6 d, range 0-20) (P = 0.0001). Severe diarrhoea (3% vs. 25%; P = 0.01) and emesis (9% vs. 34%; P = 0.01) were also reduced in group A in comparison with group B. No differences were observed between the two groups for haematological recovery. This retrospective study strongly suggests that amifostine can reduce severe mucositis and the use of analgesic drugs in this setting. A randomized study is warranted to confirm these preliminary results.
authors.affiliation: Department of Haematology, University of Ancona, Torrette Hospital, Ancona, Italy. clinemat@popsci.unian.it
authors.forename: D
authors.initials: D
authors.lastname: Capelli
authors.forename: G
authors.initials: G
authors.lastname: Santini
authors.forename: C
authors.initials: C
authors.lastname: De Souza
authors.forename: A
authors.initials: A
authors.lastname: Poloni
authors.forename: G
authors.initials: G
authors.lastname: Marino
authors.forename: M
authors.initials: M
authors.lastname: Montanari
authors.forename: M
authors.initials: M
authors.lastname: Lucesole
authors.forename: M
authors.initials: M
authors.lastname: Brunori
authors.forename: D
authors.initials: D
authors.lastname: Massidda
authors.forename: M
authors.initials: M
authors.lastname: Offidani
authors.forename: P
authors.initials: P
authors.lastname: Leoni
authors.forename: A
authors.initials: A
authors.lastname: Olivieri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D001772:Blood Cell Count; D003967:Diarrhea / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000009:adverse effects*; D008875:Middle Aged; D009061:Mouth Mucosa; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D012189:Retrospective Studies; D013280:Stomatitis / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology
chemical_list: D000701:Analgesics, Opioid; D018906:Antineoplastic Agents, Alkylating; D011837:Radiation-Protective Agents; D004999:Amifostine; D008558:Melphalan